Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Imprinted antibody responses against SARS-CoV-2 Omicron sublineages.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • المصدر:
      Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 0404511 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1095-9203 (Electronic) Linking ISSN: 00368075 NLM ISO Abbreviation: Science Subsets: MEDLINE
    • بيانات النشر:
      Publication: : Washington, DC : American Association for the Advancement of Science
      Original Publication: New York, N.Y. : [s.n.] 1880-
    • الموضوع:
      Antibodies, Neutralizing*/immunology ; Antibodies, Viral*/immunology ; Antibody Formation* ; COVID-19*/immunology ; SARS-CoV-2*/genetics ; SARS-CoV-2*/immunology ; Spike Glycoprotein, Coronavirus* ; Immune Evasion*; Humans ; Neutralization Tests ; Immunologic Memory ; Memory B Cells/immunology
    • نبذة مختصرة :
      Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineages carry distinct spike mutations resulting in escape from antibodies induced by previous infection or vaccination. We show that hybrid immunity or vaccine boosters elicit plasma-neutralizing antibodies against Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5, and that breakthrough infections, but not vaccination alone, induce neutralizing antibodies in the nasal mucosa. Consistent with immunological imprinting, most antibodies derived from memory B cells or plasma cells of Omicron breakthrough cases cross-react with the Wuhan-Hu-1, BA.1, BA.2, and BA.4/5 receptor-binding domains, whereas Omicron primary infections elicit B cells of narrow specificity up to 6 months after infection. Although most clinical antibodies have reduced neutralization of Omicron, we identified an ultrapotent pan-variant-neutralizing antibody that is a strong candidate for clinical development.
    • Comments:
      Update of: bioRxiv. 2022 Aug 22:2022.05.08.491108. doi: 10.1101/2022.05.08.491108. (PMID: 35677069)
    • Grant Information:
      DP1 AI158186 United States AI NIAID NIH HHS
    • الرقم المعرف:
      0 (Antibodies, Neutralizing)
      0 (Antibodies, Viral)
      0 (spike protein, SARS-CoV-2)
      0 (Spike Glycoprotein, Coronavirus)
    • الموضوع:
      SARS-CoV-2 variants
    • الموضوع:
      Date Created: 20221020 Date Completed: 20221121 Latest Revision: 20240125
    • الموضوع:
      20250114
    • الرقم المعرف:
      10.1126/science.adc9127
    • الرقم المعرف:
      36264829